Richard S E Keefe

发表

Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.

Richie Poulton, Avshalom Caspi, A. Caspi, 2010, The American journal of psychiatry.

Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies

Philip D. Harvey, Philip D Harvey, Delbert G Robinson, 2010, Neuropsychopharmacology.

Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.

Jimmy Lee, Alex Fornito, Christos Pantelis, 2014, Schizophrenia bulletin.

Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Herbert Y Meltzer, Anil K Malhotra, A. Malhotra, 2008, Neuropsychopharmacology.

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.

Ellen Frank, Shelby D Reed, Helena C Kraemer, 2013, Innovations in clinical neuroscience.

Measuring outcome priorities and preferences in people with schizophrenia

Marvin Swartz, Jeffrey Lieberman, Diana Perkins, 2005, British Journal of Psychiatry.

Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.

Godfrey D Pearlson, Carol A Tamminga, Elliot S Gershon, 2013, The American journal of psychiatry.

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.

Philip D. Harvey, Philip D Harvey, R. Keefe, 2007, Schizophrenia bulletin.

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

Michael F. Green, Philip D. Harvey, Philip D Harvey, 2004, The Journal of clinical psychiatry.

Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories.

Godfrey D Pearlson, Carol A Tamminga, Elliot S Gershon, 2014, Schizophrenia bulletin.

A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Steven P Reise, Robert M Bilder, S. Reise, 2011, Schizophrenia bulletin.

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Wendy J Mack, Pierre N Tariot, Mary Sano, 2011, The American journal of psychiatry.

Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

Jeffrey A Lieberman, Patrick F Sullivan, Robert E Vann, 2011, Neuropsychopharmacology.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Michael F. Green, R. Buchanan, D. Umbricht, 2011, Schizophrenia bulletin.